1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR 0.58 (significant). 2. Grade 3-4 treatment-related adverse events occurred in 32.5% in the nivolumab group vs 25.2% in the chemotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Nivolumab, an anti-PD-1 antibody, combined with chemotherapy,
1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no treatment-related grade 4-5 adverse events or fatalities reported. Evidence Rating Level: 1 (Excellent) Study Rundown: Checkpoint inhibitors are now commonly used as adjuvant therapy for resected melanoma, yet recurrence remains a concern among many patients.
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy is a
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy
ESMO 2023: Current Peri-Operative Trial Designs and Endpoints: What Do They Mean? urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.